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Abstract
Background: The catechol-O-methyltransferase (COMT) enzyme plays a crucial role in dopamine degradation, and the COMT 
Val158Met polymorphism (rs4680) is associated with significant differences in enzymatic activity and consequently dopamine 
concentrations in the prefrontal cortex. Multiple studies have analyzed the COMT Val158Met variant in relation to antipsychotic 
response. Here, we conducted a meta-analysis examining the relationship between COMT Val158Met and antipsychotic response.
Methods: Searches using PubMed, Web of Science, and PsycInfo databases (03/01/2015) yielded 23 studies investigating COMT 
Val158Met variation and antipsychotic response in schizophrenia and schizo-affective disorder. Responders/nonresponders 
were defined using each study’s original criteria. If no binary response definition was used, authors were asked to define 
response according to at least 30% Positive and Negative Syndrome Scale score reduction (or equivalent in other scales). 
Analysis was conducted under a fixed-effects model.
Results: Ten studies met inclusion criteria for the meta-analysis. Five additional antipsychotic-treated samples were analyzed for 
Val158Met and response and included in the meta-analysis (ntotal = 1416). Met/Met individuals were significantly more likely to respond 
than Val-carriers (P = .039, ORMet/Met = 1.37, 95% CI: 1.02–1.85). Met/Met patients also experienced significantly greater improvement in 
positive symptoms relative to Val-carriers (P = .030, SMD = 0.24, 95% CI: 0.024–0.46). Posthoc analyses on patients treated with atypical 
antipsychotics (n = 1207) showed that Met/Met patients were significantly more likely to respond relative to Val-carriers (P = .0098, 
ORMet/Met = 1.54, 95% CI: 1.11–2.14), while no difference was observed for typical-antipsychotic-treated patients (n = 155) (P = .65).
Conclusions: Our findings suggest that the COMT Val158Met polymorphism is associated with response to antipsychotics in 
schizophrenia and schizo-affective disorder patients. This effect may be more pronounced for atypical antipsychotics.
Keywords: COMT, Val158Met, antipsychotics, schizophrenia, clinical response
Introduction
Schizophrenia (SCZ) is a debilitating neurodevelopmental disorder 
with high heritability (~0.8) (McGuffin et al., 1995). While antipsy-
chotic drugs are currently the most effective treatment, clinical 
response varies significantly between patients, with an overall 
response rate of only 50% (Lieberman et al., 2005). The field of phar-
macogenetics aims to optimize treatment at the individual level 
by leveraging our knowledge of how genetic variants influence 
clinical response. Since all antipsychotics target the dopamine (DA) 
system to various extents by binding to dopamine D2 receptors, 
pharmacogenetics studies have largely focused on DA system-
related genes, including those encoding the dopamine D2 receptor 
(DRD2) and catechol-O-methyltransferase (COMT). Previous stud-
ies have identified associations for genes such as DRD2 and DRD3 
(dopamine D3 receptor) in relation to response to antipsychotics 
(Hwang et al., 2010; Zhang et al., 2010). Other genes implicated in 
response include 5-HT2A and 5-HT2C (Pouget and Müller, 2014).
The COMT gene is located within the 22q11 chromosomal 
locus, a region highly implicated in SCZ risk (Badner and 
Gershon, 2002; Lewis et al., 2003). The COMT enzyme plays a sig-
nificant role in cortical DA degradation (Lachman et al., 1996). The 
majority of pharmacogenetics studies examining COMT in rela-
tion to antipsychotic response have focused on the functional 
variant Val158Met (rs4680). Other putatively functional variants 
have also been examined, though relatively infrequently (Chen 
et al., 2004; Molero et al., 2007). The Val158Met variant is located 
within exon 4 of the COMT gene and involves a G-to-A nucleo-
tide switch, leading to a valine (Val) to methionine (Met) substitu-
tion at codon 158. The Met-allele form of the enzyme has lower 
thermostability and has been observed to exhibit reduced enzy-
matic activity, contributing to increased levels of cortical dopa-
mine (Chen et al., 2004); the Met/Met homozygote has 3- to 4-fold 
lower enzymatic activity than the Val/Val homozygote, while the 
heterozygote has intermediate activity (Chen et al., 2004).
Studies of COMT Val158Met and antipsychotic response in 
SCZ and schizo-affective disorder have yielded mixed results. 
A number of studies have observed that the Met-allele is asso-
ciated with better overall clinical response as well as greater 
improvement in negative symptoms and cognitive abilities such 
as working memory (Bertolino et  al., 2004, 2007; Molero et  al., 
2007; Woodward et al., 2007; Pelayo-Terán et al., 2011). However, 
other studies have either been unable to replicate these find-
ings (Yamanouchi et al., 2003; Gao et al., 2012; Tybura et al., 2012; 
Bishop et  al., 2015) or observed the opposite effect, with the 
Met-allele predicting nonresponse to antipsychotic therapy (Illi 
et al., 2003; Porcelli et al., 2009). In an effort to clarify the COMT 
Val158Met variant’s role in antipsychotic response, we conducted 
a meta-analysis of the existing literature plus additional data. In 
our primary analysis, we examined the association between this 
variant and both binary and continuous measures of response 
to antipsychotics. The meta-analysis focused solely on clinical 
response to antipsychotics, since the overwhelming majority of 
Val158Met pharmacogenetics studies examined this phenotype.
Methods and Materials
Literature Search
A literature search was conducted for articles written in English 
published up to March 1, 2015, examining the COMT Val158Met 
variant and antipsychotic response in SCZ and schizo-affective 
disorder patients. We performed searches on PubMed, PsychInfo, 
and Web of Science using all combinations of the key terms 
‘COMT,’ ‘Catechol O-methyltransferase,’ and ‘Val158Met,’ with the 
phrases ‘antipsychotic response’ and ‘SCZ treatment response.’ 
Criteria for inclusion in the current study consisted of: (1) the 
association between the COMT Val158Met polymorphism and 
antipsychotic response was assessed; (2) the patients were 
diagnosed with SCZ or schizoaffective disorder based on DSM-
III, DSM-IV, DSM-V, or ICD-10 criteria and their diagnoses were 
verified through a standardized structured clinical interview; (3) 
antipsychotic response was evaluated according to a standard-
ized clinical rating scale, such as the Brief Psychiatric Rating Scale 
(BPRS) or the Positive and Negative Syndrome Scale (PANSS); (4) 
drug response (symptom severity) was evaluated at a minimum 
of 2 time points, one of which was directly prior to starting antip-
sychotic therapy; and (5) patients were evaluated for a minimum 
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of 2 weeks for response to treatment. Studies investigating non-
clinical aspects of response, such as cognitive response, were 
excluded. We also searched through the reference sections of arti-
cles meeting these criteria to find other articles fit for inclusion. 
Authors were contacted for data when the data necessary for 
analysis was not reported in articles that met inclusion criteria.
In total, the literature search yielded 23 peer-reviewed articles 
published before March 1, 2015. Two of these articles were identified 
through searching the reference sections of the other 21 articles 
(Porcelli et al., 2009; Kang et al., 2010). The literature search process 
is outlined in Figure 1. In total, 15 articles met inclusion criteria for 
the current study. However, 11 of the 15 studies did not have group-
level data (ie, number of responders/nonresponders) available 
online (Molero et al., 2007; Ikeda et al., 2008; Fijal et al., 2009; Need 
et al., 2009; Porcelli et al., 2009; Kang et al., 2010; Gao et al., 2012; 
Tybura et al., 2012; Zhao et al., 2012; Bishop et al., 2015; Bosia et al., 
2015). Another 2 studies focused on first-episode psychosis and 
did not provide the response/nonresponse data for its subset of 
SCZ or schizo-affective disorder patients (Pelayo-Terán et al., 2011; 
Prata et al., 2012). We attempted to contact each of these groups 
and obtained data from 7 of these studies (Molero et al., 2007; Ikeda 
et al., 2008; Porcelli et al., 2009; Pelayo-Terán et al., 2011; Gao et al., 
2012; Tybura et al., 2012; Bishop et al., 2015). The studies for which 
we were unable to retrieve the required data were excluded (Fijal 
et al., 2009; Need et al., 2009; Kang et al., 2010; Prata et al., 2012; 
Zhao et al., 2012; Bosia et al., 2015). We added data from 5 additional 
samples that our group has published on previously (Hwang et al., 
2012; Zai et al., 2012; Tiwari et al., 2013; Gonçalves et al., 2014) to 
these 10 studies’ samples to give a total of 15 samples (ntotal = 1416). 
Two of these samples had previously been analyzed for Val158Met 
and antipsychotic response (Nolan et  al., 2006), while the other 
3 had not been. Figure 1 illustrates the literature search process. 
The demographic and clinical characteristics of the 15 samples are 
described in Table 1. All 15 samples included data for the number 
of responders and nonresponders. Ten of these samples also had 
data for change in total score (%). Of these 10 samples, 6 further 
included positive and negative symptom subscale score change 
data. We later contacted the authors for studies with a mix of atyp-
ical and typical-antipsychotic-treated patients to obtain response 
data for each antipsychotic type separately.
Subjects from Toronto Samples
The 5 samples from Toronto in this analysis included Toronto 
samples (TS)1–5. TS1 (Lieberman, N = 58) was collected at 4 psy-
chiatric state hospitals in New York and North Carolina. These 
patients met DSM-IV criteria for chronic SCZ and or schizo-
affective disorder. They exhibited suboptimal response to prior 
treatment, defined primarily by persistent positive symptoms 
and poor functioning for the past 2  years. The patients were 
recruited as part of a 14-week, randomized, double-blinded 
study and response was evaluated using the PANSS scale. This 
sample is also described in greater detail elsewhere (Volavka 
et  al., 2004). TS2 (Müller, N = 89) was collected at Charité 
University Medicine, Berlin, Germany. Patients were diagnosed 
with SCZ or schizo-affective disorder according to DSM-IV or 
ICD-10 criteria and treated with several different antipsychotics. 
This sample is described in more detail elsewhere (Müller et al., 
2012). TS3 (Meltzer, N = 90), 4 (Lieberman, N = 90), and 5 (Potkin, 
N = 32) were collected from Case Western Reserve University 
in Cleveland, Ohio, Zucker Hillside Hospital in Glen Oaks, New 
York, and University of California at Irvine, respectively. Subjects 
from TS3-5 had DSM-III-R or DSM-IV diagnoses of SCZ and met 
criteria for treatment refractoriness or intolerance to traditional 
antipsychotic therapy. After a 2- to 4-week washout period, 
patients were treated with clozapine and evaluated prospec-
tively for 6 months, during which blood levels of clozapine were 
monitored to confirm treatment adherence. Treatment response 
was evaluated using the 18-item BPRS (Overall and Gorham, 
1962) at the beginning and end of treatment. These samples 
are described in greater detail elsewhere (Hwang et  al., 2005). 
Analysis of response in each of these samples is discussed in the 
section “Definition of Response.” The ethnicities of patients from 
all 5 samples are described in Table 1.
Figure 1. Literature search process results.
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Definition of Clinical Response
Clinical responders and nonresponders were defined based on 
the criteria applied within each original study separately. If a 
study did not report the antipsychotic response data in binary 
responder/nonresponder form, study investigators were con-
tacted and requested to apply a response threshold of 30% 
change in PANSS score or the equivalent in the clinical rating 
scale used in their study. The 30% cutoff was adopted for the cur-
rent study, as it was the most commonly applied criteria in the 
studies included in the meta-analysis. We used the conversion 
scale of Leucht et al. (2013) to calculate corresponding response 
thresholds for other rating scales. For instance, according to 
this scale, the equivalent score change in the BPRS scale is 35%. 
For TS4, only responder/nonresponder data were available, for 
which response was defined as >20% reduction in overall BPRS 
score after 6  months of treatment based on criteria proposed 
by Kane et al. (1988). Thus, we had no option but to utilize this 
response definition for this sample. Overall, 14 of the 15 samples 
used the 30% PANSS score change (or equivalent) response cri-
teria. Nonclinical dimensions of response, such as improvement 
in cognition, were not analyzed.
Genotyping
For the Toronto samples, genomic data were extracted using the 
high-salt method from venous blood (Lahiri and Nurnberger, 
1991). The COMT Val158Met (rs4680) variant was genotyped 
using Taqman 5’ nuclease assay (Applied Biosystems; Foster 
City, CA). All ambiguous genotypes were retyped. Genotypes 
that remained ambiguous were excluded from further analyses. 
Genotyping accuracy was assessed by repeating genotyping for 
10% of the sample, and results showed 100% concordance.
Statistical Analysis
All data were analyzed using R statistical software (v3.1.1). 
Meta-analysis was performed using the ‘meta’ package, version 
4.1-0 (Guido Schwarzer, University of Freiburg). Fixed effects 
models were used for each analysis, consistent with approaches 
commonly used in pharmacogenetic meta-analyses (Serretti 
et al., 2007; Zhang et al., 2010). In our primary analysis, separate 
meta-analyses were conducted assuming three genetic mod-
els: recessive (Met/Met vs Val-allele carriers), dominant (Val/
Val vs Met-allele carriers), and allelic (Val vs Met  allele). All 3 
models were used to test the association of COMT Val158Met 
with numbers of treatment responders vs nonresponders. 
Odds ratios and 95% CIs were computed and pooled using the 
Mantel-Haenszel method to determine overall effect sizes. We 
also examined each genetic model in relation to total symp-
tom score change (%), positive subscale score change (%), and 
negative subscale score change (%) in a subset of study sam-
ples for which data were available (total: studies = 10, n = 1085; 
subscales: studies = 6, n = 616). Effect sizes were analyzed by 
computing SMD. Heterogeneity was assessed using Cochran’s Q 
test. Meta-regression was used to check for confounding effects 
due to the following variables: self-reported ethnicity, SCZ type 
(first-episode vs non-first episode), antipsychotic type (atypical-
only vs mixed; specific drugs), age of onset, sex, study design (eg, 
prospective, naturalistic), duration of study, drug naïve vs prior 
exposure, and criteria for response. Publication bias was evalu-
ated using the Harbord test (Harbord et al., 2006) and the funnel 
plot method (“metabias” and “funnel” commands, respectively). 
Sensitivity analyses were conducted on any significant findings 
(P < .05) by removing the studies with the largest and smallest 
effect sizes, as in other antipsychotic pharmacogenetic meta-
analyses (Zhang et al., 2010).
To dissect the factors (eg, ancestry, antipsychotic type) 
contributing to the observed genetic effect, we examined the 
association between genotype and number of responders/
Table 1. Characteristics of Studies Investigating the Association between COMT Polymorphism Val158Met and Antipsychotic Drug Response in 
Schizophrenia/Schizo-Affective Disorder Patients
Study/Sample N Ethnicity MAF Design Medication
Response  
Criteria
Responders/
Nonresponders
Bertolino et al., 2004 30 EU 0.45 Prospective Olanzapine PANSS 30% ↓ 14 / 16
Bertolino et al., 2007 29 EU 0.59 Prospective Olanzapine PANSS 30% ↓ 14 / 15
Bishop et al., 2014* 61 EU, AA, AS, HS, O 0.41 Prospective Various BPRS 35% ↓ 10 / 51
Toronto Sample 1 58 EU, AA, O 0.38 Prospective, Randomized Various PANSS 30% ↓ 10 / 48
Gao et al., 2012 83 AS 0.39 Prospective Risperidone PANSS 30% ↓ 69 / 14
Toronto Sample 2 89 EU, AA 0.51 Naturalistic Various PANSS 30% ↓ 59 / 30
Gupta et al., 2009 117 SI 0.37 Naturalistic Risperidone CGI 2 or less 69 / 48
Toronto Sample 3* 90 EU, AA 0.44 Prospective Various BPRS 35% ↓ 31 / 59
Toronto Sample 4 90 EU, AA 0.43 Prospective Clozapine BPRS 20% ↓ 55 / 35
Molero et al., 2007 205** EU 0.46 Naturalistic, Prospective Various PANSS 30% ↓ 148 / 57
Pelayo-Teran et al., 2011 99 EU 0.40 Prospective, Randomized Various BPRS 35% ↓ 134 / 27
Porcelli et al., 2009* 144 EU 0.45 Prospective Various PANSS 30% ↓ 37 / 107
Toronto Sample 5* 35 EU, AA 0.24 Prospective Clozapine BPRS 35% ↓ 13 / 22
Tybura et al., 2012* 179** EU 0.44 Naturalistic, Randomized Various PANSS 30% ↓ 90 / 89
Ikeda et al., 2008* 107** AS 0.30 Prospective Risperidone PANSS 30% ↓ 58 / 49
Abbreviations: AA, African American; AS, Asian; BPRS, Brief Psychiatric Rating Scale; CGI, Clinical Global Impressions Scale; EU, European; HS, Hispanic; MAF, minor 
allele frequency; O, other; PANSS, Positive and Negative Symptom Scale; SI, South Indian.
*Positive and negative subscale scores available.
**N reflects additional subjects not included in original publication.
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nonresponders in samples of European ancestry (studies = 10, 
ntotal = 929). We focused on this ancestry group, as it constituted 
the majority of the samples. Ancestry may be important due to 
significant differences in Val158Met  allele frequency between 
ethnicities. Moreover, since antipsychotic type showed a trend-
level association with response, we examined the association 
between Val158Met and number of responders vs nonresponders 
in atypical and typical antipsychotic-treated patients separately.
With regards to correction for multiple testing, our approach 
is in line with that of prior pharmacogenetic meta-analyses in 
that we did not correct for the multiple genetic models tested 
when analyzing single genetic variants due to high correlations 
between the models (Bakker et al., 2006, 2008; Zhang et al., 2010).
Results
Primary Analyses
We observed a significant association with number of respond-
ers/non-responders under the recessive model (Met/Met vs 
Val-allele carriers) (P = .039, ORMet/Met = 1.37, 95% CI: 1.02–1.85) 
(Figure  2; Table  2). We also observed a trend-level association 
for total score change (P = .087, SMD = 0.14, 95% CI: -0.020–0.30) 
under a recessive model. Upon examination of the subscales, 
we observed a significant effect of Val158Met on positive symp-
tom response also under a recessive model (P = .030, SMD = 0.24, 
95% CI: 0.024–0.46). No significant associations of Val158Met 
genotype were observed for any other response measures under 
any genetic model (all P > .05). The Cochran chi-squared test did 
not reveal any significant heterogeneity for the recessive model 
in relation to number of responders/non-responders (P = .37, 
Q = 15.07, df = 14, I2 = 7.1%) or for the other genetic models and 
response measures (all Cochran test P > .05). Funnel plot analysis 
and the Harbord test revealed no evidence of publication bias for 
the recessive model in relation to number of responders/nonre-
sponders (P = .35) (Figure 3) or for the other genetic models.
To screen for potentially undetected heterogeneity, we 
employed the sensitivity analysis conducted by Zhang et  al. 
(2010) in their pharmacogenetic meta-analysis (Zhang et  al., 
2010), excluding the 2 studies with the largest (Bertolino et al., 
2004) and smallest effect sizes (Ikeda et al., 2008). Sensitivity anal-
ysis was conducted for the association between the Val158Met 
variant and number of responders/nonresponders under the 
recessive model. This revealed no undetected heterogeneity and 
no significant influence on overall effect. After exclusion of the 
2 studies, the significance of the association increased slightly 
(P = .012), while the effect size remained the same (OR = 1.54, 95% 
CI: 1.10–2.15) and the heterogeneity decreased (I2 = 0%, P = .65).
Meta-regressions including potential confounding vari-
ables revealed a trend for antipsychotic type (atypical-only vs 
mixed) as a predictor of response rate across studies (P = .055). 
Figure 2. All studies. Meta-analysis of the association between the Val158Met polymorphism (Met/Met vs Val carrier) and antipsychotic drug response: forest plot.
Table  2. Primary Analysis Results: All Studies (n = 15; total sample 
size = 1416).
Genetic Model
Association Effect Size  
(Odds Ratio, 95% CI)
Significance  
(P-Value)
Recessive
(M/M vs V/M and V/V)
1.37 (1.02–1.85) 0.039*
Dominant
(M/M and V/M vs V/V)
1.07 (0.83–1.37) 0.58
Allelic (M vs V) 1.13 (0.96–1.34) 0.14
 Abbreviations: M/M, Met/Met genotype; V/M, Val/Met genotype; V/V, Val/Val 
genotype.
*Denotes significance (P < .05).
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We could not include the variable of atypical vs typical antipsy-
chotic-treated samples, as there were no studies with patients 
exclusively treated with typical antipsychotics. None of the 
remaining potential confounders tested were associated with 
response rate: gender, ethnicity, first episode vs non-first epi-
sode, treatment duration, study design, age at onset, drug-naïve 
vs prior exposure, and criteria for response.
Posthoc Analyses
Since the meta-regression revealed antipsychotic type (atypical 
vs mixed) to be a potential predictor of response (P = .055), analy-
ses were conducted separately on patients treated with atypical 
antipsychotics (studies = 15; ntotal = 1207) and typical antipsy-
chotics (studies = 7; ntotal = 155). The 7 studies with typical antip-
sychotic-treated patients also included patients treated with 
atypical antipsychotics, but these were excluded for this anal-
ysis. In the subsample of patients treated with atypical antip-
sychotics, significant differences in the number of responders/
nonresponders were observed under a recessive genetic model 
(Met/Met vs Val-allele carriers), whereby patients with Met/Met 
genotype experienced improved clinical response relative to Val 
carriers (P = .0098, OR = 1.54, 95% CI: 1.11–2.14) (Figure 4; Table 2). 
Additionally, allelic analyses revealed that the Met-allele was 
associated with greater likelihood of response compared to 
the Val-allele (P = .043, OR = 1.20, 95% CI: 1.01–1.44) (supplemen-
tary Figure  1; Table  2). No association was observed between 
Val158Met and response/nonresponse in the subsample of 
patients treated with typical antipsychotics (Table 3).
In the subsample of atypical antipsychotic-treated patients, 
Cochran’s chi-square test revealed that heterogeneity was not 
significant under the recessive (I2 = 0%, P = .52) or allelic models 
(I2  = 0%, P = .50). After excluding the 2 studies with the largest 
(Bertolino et  al., 2004) and smallest effect sizes (Molero et  al., 
2007), sensitivity analyses revealed no undetected heterogeneity 
and no significant influence on overall effect under the reces-
sive or allelic models. Further analyses revealed no significant 
publication bias (supplementary Material; Figure 5). The effect 
remained significant when analyzing only samples for which 
response was defined as 30% PANSS score reduction (stud-
ies = 14, n = 1317) (I2 = 13.8%, P = .046).
Due to significant differences in Val158Met allele frequency 
between ethnicities (ASN: 0.29, EUR: 0.52, AFR: 0.31), we con-
ducted an analysis on studies with samples of European-
ancestry (studies = 10, ntotal = 929). No significant effects were 
observed for binary response/nonresponse under the recessive 
model (P = .29, OR=1.21, 95% CI=0.85–1.72); however, consistent 
with whole group analyses, a trend was observed for atypical 
antipsychotic-treated patients of European ancestry (stud-
ies = 10, ntotal = 745) (P = .061, OR = 1.45, 95% CI = 0.98–2.15), with 
Met/Met patients experiencing better response than Val-allele 
carriers. The Cochran test showed no significant heterogeneity 
under any of the genetic models (all tests P > .05). Furthermore, 
funnel plot analysis and the Harbord test did not reveal any sig-
nificant publication bias (supplementary Figure 2).
Discussion
To our knowledge, this study is the most comprehensive 
meta-analysis to investigate the relationship between COMT 
Val158Met and antipsychotic clinical response. Our meta-anal-
ysis includes data from 8 studies not reported in the original 
manuscripts and kindly provided to us by the authors (Molero 
et al., 2007; Ikeda et al., 2008; Gupta et al., 2009; Porcelli et al., 
2009; Pelayo-Terán et al., 2011; Gao et al., 2012; Tybura et al., 2012; 
Bishop et al., 2015), as well as 3 samples previously not investi-
gated for Val158Met and antipsychotic response (TS2, TS3, TS5). 
Thus, our study provides a much-expanded sample compared 
with a previous meta-analysis (Chen et al., 2015). More impor-
tantly, all samples included in our meta-analysis were analyzed 
for response/nonresponse according to uniform criteria (PANSS 
30% reduction or equivalent), with the exception of one (TS4), 
minimizing inter-study heterogeneity.
Overall, significant effects of Val158Met on response vs 
nonresponse, as well as positive symptom improvement, were 
observed. The association was stronger when restricting the 
analysis to studies with atypical antipsychotic-treated sam-
ples (eg, clozapine, olanzapine, risperidone). Overall, Met-allele 
homozygotes experienced improved response compared with 
Val-allele carriers.
These results are consistent with previous studies finding that 
the Met-allele is associated with improved cognitive response 
Figure 3. All studies. Meta-analysis of the association between the Val158Met polymorphism (Met/Met vs Val carrier) and antipsychotic drug response: funnel plot and 
regression plot.
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to atypical antipsychotics (Bertolino et al., 2004; Weickert et al., 
2004; Woodward et  al., 2007). These studies evaluated cogni-
tive response using tests such as the Wisconsin Card Sorting 
Test that evaluate cognitive abilities including working mem-
ory, executive function, and attention (Weickert et  al., 2004). 
Conceivably, improvements in clinical symptoms, particularly 
positive symptoms, may contribute to cognitive improvement. 
Alternatively, improvements in clinical symptoms may be 
mediated by improvement in cognitive function (Censits et al., 
1997; Velligan et al., 1997; Gold et al., 1999; Hoff et al., 1999); in 
particular, improved working memory and executive function 
could lead to improved treatment compliance and adherence 
to psychiatrist recommendations, resulting in improved clini-
cal outcome. Cognitive response data were available in 3 of the 
studies included in the meta-analysis. Consistent with previ-
ous findings, Bertolino et al. (2004) observed that the Met-allele 
predicted better working memory response to olanzapine as 
measured by the N-back task (Bertolino et al., 2004). The 2 other 
studies did not observe an association between Val158Met and 
improvement in memory function or cognitive flexibility (Gao 
et al., 2012) and spatial working memory (Bishop et al., 2015) in 
response to antipsychotic treatment, respectively. The reasons 
for this are not clear but may relate to antipsychotic drug-type 
(both these samples were treated either largely or entirely with 
risperidone) and cognitive assessment methods (ie, Bishop et al. 
assessed spatial working memory). However, it should be noted 
that Gao et al. (2012) observed the same direction effect as previ-
ous studies, with the Met-allele appearing to experience greater 
improvement in orientation, comprehension, and experiential 
and number memory (Gao et al., 2012).
The findings are also consistent with the tonic-phasic DA 
hypothesis as applied to antipsychotic response. According to 
this hypothesis, DA regulation in limbic striatal regions occurs 
through transient, high-amplitude, phasic DA release and per-
sistent low-level tonic DA release modulated by corticostriatal 
glutamatergic afferents. In these regions, tonic DA release also 
Table 3. Post Hoc Analysis Results – Atypical and Typical-Antipsychotic Patient Subsamples
Genetic Model
Atypical
Association Effect Size  
(Odds Ratio, 95% CI) (n = 1207)
Significance
(P-Value)
Typical
Association Effect Size 
(Odds Ratio, 95% CI)
(n = 155)
Significance
(P-Value)
Recessive
(M/M vs V/M and V/V)
1.54 (1.11–2.14) 0.0098* 0.78 (0.36–1.70) 0.54
Allelic
(M vs V)
1.20 (1.01–1.44) 0.043* 0.78 (0.49–1.22) 0.27
Abbreviations: M/M, Met/Met genotype; V/M, Val/Met genotype; V/V, Val/Val genotype.
*Denotes significance (P < .05).
Figure 4. Atypical antipsychotic-treated samples. Meta-analysis of the association between the Val158Met polymorphism (Met/Met vs Val carrier) and antipsychotic 
drug response: forest plot.
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decreases phasic release through the stimulation of D2 auto-
receptors at the synapse (Bilder et al., 2004). Importantly, COMT 
is involved in modulating the tonic, extracellular pool of DA sub-
cortically, as it breaks down DA that is not reabsorbed by dopa-
mine transporters. Thus, the Met-allele leads to lower COMT 
activity, higher tonic DA, and lower phasic DA release (more 
negative symptoms), while the Val-allele gives rise to lower tonic 
and higher phasic DA release (more positive symptoms) (Bilder 
et al., 2004). Bilder et al. (2004) have also suggested that D1 recep-
tors are more important for modulating tonic release, while 
D2 receptors are more critical for regulating phasic DA release 
(Bilder et al., 2004). Therefore, the COMT Val158Met variant may 
have different effects on response to different classes of antipsy-
chotics. Specifically, they suggest that the Met-allele may predict 
better response to agents enhancing D1-transmission (5-HT2A-
antagonists and/or 5-HT1A-agonists or partial agonists), since 
they are thought to increase tonic DA transmission (Bilder et al., 
2004). These agents include the majority of atypical antipsychot-
ics. The Val-allele, in contrast, is hypothesized to predict better 
response to conventional D2-blocking agents (ie, typical antip-
sychotics), as they decrease phasic DA transmission.
Our findings for positive symptoms may also be consist-
ent with the tonic-phasic DA hypothesis. Based on the predic-
tions of Bilder et al., the Met-allele may also predict improved 
response in positive symptoms due to lower phasic DA trans-
mission subcortically, which could potentiate the effects of 
antipsychotic-induced D2 receptor blockade. This prediction 
is supported by previous findings that the Met-allele is associ-
ated with greater dopamine synthesis in the midbrain and thus 
lower striatal dopaminergic stimulation (Meyer-Lindenberg 
et  al., 2005). Moreover, consistent with this theory, reduced 
COMT activity has been observed to potentiate clozapine-
induced DA release in the prefrontal cortex (PFC) (Tunbridge 
et  al., 2004). By the tonic-phasic DA hypothesis, increased DA 
release in the PFC leads to greater D1 receptor activation, stimu-
lating greater glutamate release from pyramidal neurons onto 
the nucleus accumbens. This, in turn, increases tonic DA release, 
subsequently decreasing phasic DA release and thus reducing 
positive symptom severity (Bilder et al., 2004). Specific atypical 
antipsychotics such as risperidone and olanzapine have also 
been observed to upregulate COMT mRNA expression in the rat 
PFC (Chen and Chen, 2007), suggesting a direct effect of these 
drugs on COMT activity.
The observed null genetic effect in typical-antipsychotic-
treated patients may be a product of lack of statistical power, as 
the majority of patients were treated with atypical antipsychot-
ics (typical: n = 155, atypical: n = 1207). Ultimately, it is possible 
that analyses conducted in larger samples could reveal associa-
tions of Val158Met with response in subjects treated with typical 
antipsychotics. Further, we acknowledge that differences among 
specific drugs within each class of antipsychotics, rather than 
broader class differences between atypical and typical antipsy-
chotics, may be driving the results. However, due to limited data, 
this could not be tested.
The direction of genetic effect was consistent across 11 of 
the 15 samples in both the analysis of total sample as well as 
of atypical-antipsychotic-treated patients alone. The four sam-
ples observing a genetic effect in the opposite direction included 
TS1, Molero et al. (2007), Gao et al. (2007), and Ikeda et al. (2008). 
Notably, these 4 samples’ effects were all nonsignificant (95% 
CI of OR encompasses 1), leaving open the possibility that the 
opposite directions of effect may be due to random chance. It is 
possible that ancestry-related differences in the frequencies of 
COMT genetic variants other than Val158Met may explain these 
results. For instance, the functional variant Ala72Ser (rs6267), 
which is not in LD with Val158Met, also alters COMT activ-
ity and exists only in East-Asian populations (MAF: 0.07–0.11) 
(Gupta et al., 2011). Functional investigations suggest that this 
variant may exert its effect additively together with Val158Met, 
whereby presence of both low-activity alleles results in lower 
COMT activity than possession of either allele alone (Lee et al., 
2005). Thus, while ancestry-related differences in MAF and 
COMT genetic variation may provide insight into the opposite 
direction of effect observed, we did not have sufficient sam-
ples of Asian ancestry to test for ancestry-specific associations. 
Another sample showing an opposite direction of effect, TS1, 
was highly treatment-resistant and included only 4 respond-
ers compared with 54 nonresponders; this lack of statistical 
power likely contributed to the null genetic effect observed in 
this sample. Finally, none of the 4 samples deviated from Hardy-
Weinberg equilibrium (HWE) (P < .05), ruling this out as a possible 
explanation.
Figure 5. Atypical antipsychotic-treated samples. Meta-analysis of the association between the Val158Met polymorphism (Met/Met vs Val carrier) and antipsychotic 
drug response: funnel plot and regression plot.
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In addition, Molero et al. (2007) may have observed a non-
significant effect for Val158Met in their sample due to several 
reasons. First, their sample differed from the majority of other 
samples in that the study specifically included patients who had 
recently experienced an acute worsening of psychotic symp-
toms, leading to uniquely high initial scores (average PANSS 
score: ~90). Second, the Val-allele carriers had significantly 
higher PANSS scores compared with Met-allele homozygotes at 
the study’s beginning. Since baseline score has been observed to 
predict overall response, this score differential may have con-
tributed to greater score change for Val-allele carriers and thus a 
higher number of responders. Importantly, Met-allele homozy-
gotes had significantly lower PANSS scores than Val-allele carri-
ers at the end of the 6 months of treatment, which is consistent 
with findings from other studies in the meta-analysis.
The present meta-analysis had several limitations. First, 
while we attempted to test and control for possible confounding 
factors, several factors could not be accounted for due to lack 
of data availability. These include pharmacological aspects of 
treatment response, such as drug dose or concentrations, as well 
as environmental factors, such as significant stress or lifetime 
exposure to psychosis-inducing drugs. Nevertheless, it should 
be noted that no confounding effects were observed for the 
variables tested, except for antipsychotic type (trend observed). 
Moreover, heterogeneity across studies was not significant for 
any of the genetic models or response measures evaluated, sug-
gesting minimal confounding by unidentified factors. Second, 
although we did not observe a significant influence of ethnic-
ity in our samples, it should be noted non-European ethnici-
ties were underrepresented. This imbalance may be important, 
since, as mentioned previously, Val158Met allele frequencies dif-
fer considerably among ethnic groups. Nevertheless, the fact that 
the sample consisted of mostly patients of European ancestry 
helps reduce heterogeneity in the sample. Third, it should also 
be noted that the genotypes in the sample from Pelayo-Teran 
et al. (2011) were not in HWE (P < .05). However, the skewing effect 
due to non-HWE should be minimal, as removing this sample 
did not impact the overall genetic effect observed or the level 
of heterogeneity. Lastly, if we were to apply a Bonferroni correc-
tion threshold, the association observed between Val158Met and 
number of responders/nonresponders in the total sample would 
be nonsignificant. However, given the high correlation between 
the genetic models applied and phenotype measures of response, 
this method for correction would be overly conservative.
Overall, our meta-analysis provides evidence that COMT 
Val158Met is associated with response to antipsychotics, with a 
stronger effect observed for atypical antipsychotics. Prospective 
studies with complete categorical and continuous response 
measure data that differentiate between atypical and typi-
cal antipsychotics would help in strengthening the evidence 
of this functional variant’s relationship with antipsychotic 
response. Future studies of COMT should also include other 
putatively functional variants such as rs6267, rs737865, and 
rs4818 (SZGene Data Base, Nature Genetics, 2008)  (Bray et  al., 
2003; Chen et al., 2004) in order to obtain a more comprehen-
sive understanding of how genetically predicted COMT func-
tion may influence antipsychotic response. Moreover, given the 
complexity of the antipsychotic response phenotype, it is likely 
that other genetic, environmental, and potentially epigenetic 
factors are involved, which were beyond the scope of this study. 
Notably, several findings provide evidence for multiple gene-
gene interaction and gene-environment interactions involving 
COMT (Nicodemus et al., 2007). Moving forward, investigations 
of epistatic and gene-environment interactions involving COMT 
should further improve our understanding of this gene’s effect 
on antipsychotic response. Nevertheless, our findings suggest 
that COMT Val158Met may warrant closer consideration in ran-
domized clinical trials. Since this variant appears to associate 
with response, balancing each arm of a RCT so that the same 
percentage of Met/Met are represented in each arm may prevent 
COMT genetic imbalance from confounding the efficacy results.
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